Clinical trial

Comprehensive Clinical Evaluation Study of GLP-1RA

Recruiting now · Not applicable · 1 countries · Registry ID NCT06686134

Recruiting nowNot applicableObservational

What this study is about

The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In accordance with the index system and evaluation rules set forth in the Management Guidelines for Comprehensive Clinical Evaluation of Drugs, the effects of GLP-1RAs drugs in real-world settings are tracked, summarised, and analysed across six dimensions: safety, effectiveness, economy, innovation, appropriateness, and accessibility. This is done with the objective of ensuring that these drugs are fully utilised in accordance with their potential benefits. The objective is to ascertain the role of medical institutions as the principal entity responsible for the comprehensive evaluation of the clinical application of drugs and to provide data that will reduce the risk of using GLP-1RAs drugs. Moreover, the objective is to ascertain the advantages of their clinical application and to guarantee the safe and rational use of drugs for patients with type 2 diabetes mellitus. The objective of this study is to facilitate the fulfilment of medical institutions' role as the primary entity responsible for the comprehensive evaluation of the clinical application of medicines. Furthermore, the study will provide data that can be used to reduce the risk of using GLP-1RAs drugs, explore the advantages of their clinical application, and guarantee the safe and rational use of medicines for patients with type 2 diabetes.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionT2DM

Full registry criteria

Inclusion Criteria: * Diagnosed with type 2 diabetes; * no study drug has been used in the last three months; * Existing hypoglycemic programs include investigational drugs; * Age ≥18 years old; * The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete; * Sign informed consent. Exclusion Criteria: * persistent influenza, autoimmune disease, or other metabolic disease; * There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome; * diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used; * Patients with severe liver and kidney function impairment and patients with malignant tumors; * Pregnant or lactating women.

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

HbA1c compliance rate4, 8, 12, and 16 weeks after the start of medication

HbA1c\<7

Weight reduction from baseline4, 8, 12, and 16 weeks after the start of medication

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Yan Li🇨🇳 Jinan, China

Open map

Yan Li, DoctorContact